Security
Sutro Biopharma, Inc. Common Stock · STRO
STRONASDAQCommon stockCurrentCIK 1382101Updated Oct 6, 2026
Name history
SUTRO BIOPHARMA INC · through Nov 8, 2018Fundamental Applied Biology Inc · through Oct 24, 2007
STRO price & chart
Loading TradingView…
NASDAQ:STRO on TradingView ↗About the company
Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 209,658,000Source | 451,832,000Source | 194,462,000Source | 262,355,000Source | 489,043,000Source | 241,988,000Source | 321,430,000Source | 403,402,000Source | 173,830,000Source | 387,207,000Source | 470,736,000Source | 406,944,000Source |
| Property, Plant and Equipment, NetUSD | 13,346,000Source | 18,997,000Source | 8,357,000Source | 14,981,000Source | 19,414,000Source | 9,363,000Source | 16,798,000Source | 20,630,000Source | 10,648,000Source | 18,190,000Source | 21,940,000Source | 24,621,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 65,927,000Source | 174,579,000Source | 54,335,000Source | 64,025,000Source | 90,788,000Source | 73,682,000Source | 106,229,000Source | 65,218,000Source | 58,130,000Source | 190,304,000Source | 69,268,000Source | 47,254,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,922,000Source | 6,655,000Source | 5,797,000Source | 7,999,000Source | 6,950,000Source | 12,484,000Source | 13,562,000Source | 31,300,000Source | 3,977,000Source | 8,616,000Source | 36,078,000Source | 7,122,000Source |
| Assets, CurrentUSD | 182,113,000Source | 405,779,000Source | 175,647,000Source | 231,630,000Source | 443,475,000Source | 220,972,000Source | 287,409,000Source | 354,582,000Source | 150,926,000Source | 343,310,000Source | 421,542,000Source | 353,153,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 10,597,000Source | 10,870,000Source | 5,504,000Source | 18,500,000Source | 10,533,000Source | 5,930,000Source | 24,875,000Source | 10,064,000Source | 5,521,000Source | 17,799,000Source | 9,846,000Source | 11,667,000Source |
| Operating Lease, Right-of-Use AssetUSD | 13,341,000Source | 19,027,000Source | 8,467,000Source | 14,836,000Source | 20,333,000Source | 9,707,000Source | 16,280,000Source | 21,594,000Source | 10,903,000Source | 17,677,000Source | 22,815,000Source | 26,443,000Source |
| Other Assets, NoncurrentUSD | 0Source | 7,172,000Source | 1,133,000Source | 50,000Source | 4,964,000Source | 1,088,000Source | 85,000Source | 5,739,000Source | 495,000Source | 7,172,000Source | 3,567,000Source | 1,855,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 296,926,000Source | 340,612,000Source | 297,779,000Source | 294,466,000Source | 336,867,000Source | 308,875,000Source | 347,241,000Source | 305,378,000Source | 306,282,000Source | 342,606,000Source | 321,087,000Source | 189,896,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 85,000Source | 82,000Source | 17,000Source | 85,000Source | 82,000Source | 17,000Source | 84,000Source | 62,000Source | 9,000Source | 83,000Source | 61,000Source | 58,000Source |
| Retained Earnings (Accumulated Deficit)USD | -931,193,000Source | -714,426,000Source | -1,054,972,000Source | -874,336,000Source | -665,639,000Source | -1,016,439,000Source | -862,837,000Source | -617,621,000Source | -977,955,000Source | -786,869,000Source | -559,408,000Source | -452,615,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 33,000Source | 106,000Source | -58,000Source | -13,000Source | -163,000Source | -101,000Source | -9,000Source | -113,000Source | 19,000Source | 39,000Source | 21,000Source | -618,000Source |
| Stockholders' Equity Attributable to ParentUSD | -87,268,000Source | 111,220,000Source | -103,317,000Source | -32,111,000Source | 152,176,000Source | -66,887,000Source | -25,811,000Source | 98,024,000Source | -132,452,000Source | 44,601,000Source | 149,649,000Source | 217,048,000Source |
| Additional Paid in Capital, Common StockUSD | 843,807,000Source | 825,458,000Source | 951,696,000Source | 842,153,000Source | 817,896,000Source | 949,636,000Source | 836,951,000Source | 715,696,000Source | 845,475,000Source | 831,348,000Source | 708,975,000Source | 670,223,000Source |
| Liabilities and EquityUSD | 209,658,000Source | 451,832,000Source | 194,462,000Source | 262,355,000Source | 489,043,000Source | 241,988,000Source | 321,430,000Source | 403,402,000Source | 173,830,000Source | 387,207,000Source | 470,736,000Source | 406,944,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 71,895,000Source | 131,291,000Source | 52,898,000Source | 74,246,000Source | 129,985,000Source | 70,811,000Source | 133,046,000Source | 79,509,000Source | 75,133,000Source | 131,893,000Source | 93,746,000Source | 66,547,000Source |
| Operating Lease, Liability, CurrentUSD | 7,960,000Source | 7,203,000Source | 6,660,000Source | 8,057,000Source | 6,933,000Source | 7,600,000Source | 7,765,000Source | 6,673,000Source | 7,783,000Source | 7,480,000Source | 6,420,000Source | 4,585,000Source |
| Accounts Payable, CurrentUSD | 7,034,000Source | 6,216,000Source | 3,356,000Source | 4,308,000Source | 6,086,000Source | 5,485,000Source | 8,180,000Source | 7,511,000Source | 7,565,000Source | 10,475,000Source | 9,440,000Source | 4,797,000Source |
| Operating Lease, Liability, NoncurrentUSD | 9,701,000Source | 17,661,000Source | 4,123,000Source | 11,536,000Source | 19,593,000Source | 6,032,000Source | 13,632,000Source | 21,397,000Source | 7,891,000Source | 15,674,000Source | 23,154,000Source | 29,574,000Source |
| Other Liabilities, NoncurrentUSD | 1,694,000Source | 1,694,000Source | 1,694,000Source | 1,694,000Source | 1,694,000Source | 1,694,000Source | 1,694,000Source | 1,694,000Source | 1,694,000Source | 1,694,000Source | 1,694,000Source | 119,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 13,248,000Source | 13,177,000Source | 6,185,000Source | 11,764,000Source | 9,940,000Source | 5,354,000Source | 11,554,000Source | 7,077,000Source | 14,642,000Source | 12,905,000Source | 14,686,000Source | 13,142,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 2,702,000Source | 3,822,000Source | 13,073,000Source | 11,146,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | — | — | — | — | — | — | —Source | —Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | 4,061,000Source | 12,500,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 3,771,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -38,484,000Source | -75,968,000Source | -191,086,000Source | -227,461,000Source | -106,793,000Source | -119,204,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 1,278,000Source | 1,900,000Source | 7,324,000Source | 7,218,000Source | 6,816,000Source | 5,690,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,562,000Source | 5,538,000Source | 14,008,000Source | 24,687,000Source | 24,908,000Source | 26,304,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 8,507,000Source | 4,946,000Source | -4,639,000Source | -27,462,000Source | 28,956,000Source | -5,341,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -2,547,000Source | -1,881,000Source | -2,468,000Source | 706,000Source | 4,812,000Source | -1,225,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -42,259,000Source | -67,883,000Source | -177,231,000Source | -191,540,000Source | -111,616,000Source | 3,549,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -45,264,000Source | -16,258,000Source | 45,013,000Source | 218,508,000Source | -3,924,000Source | -35,022,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 160,000Source | 180,000Source | 332,000Source | 509,000Source | 490,000Source | 463,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 103,075,000Source | 66,000Source | 44,000Source | 94,054,000Source | 137,554,000Source | 48,313,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 15,552,000Source | -84,075,000Source | -132,174,000Source | 121,022,000Source | 22,014,000Source | 16,840,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 66,785,000Source | 175,436,000Source | 55,193,000Source | 64,883,000Source | 74,540,000Source | 107,087,000Source | 58,988,000Source | 191,162,000Source | 70,140,000Source | 48,126,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 0Source | 310,000Source | 1,126,000Source | 1,869,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | -15,000Source | 7,000Source | 75,000Source | 17,520,000Source | 379,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,552,000Source | 6,545,000Source | 2,010,000Source | 5,263,000Source | 1,562,000Source | 5,538,000Source | 14,008,000Source | 24,687,000Source | 24,908,000Source | 26,304,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | 0Source | 32,139,000Source | — | 4,074,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | — | — | — | 0Source | — | 0Source | 0Source | 0Source | 9,917,000Source | 12,130,000Source |
| General and Administrative ExpenseUSD | — | — | 8,741,000Source | 14,331,000Source | 7,831,000Source | 10,343,000Source | 7,584,000Source | 13,273,000Source | 41,019,000Source | 48,453,000Source | 62,584,000Source | 59,544,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 1,000Source | -18,000Source | -15,000Source | 7,000Source | -93,000Source | 2,363,000Source | 18,192,000Source | 2,500,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -56,857,000Source | -48,787,000Source | -38,533,000Source | -11,499,000Source | -38,484,000Source | -75,968,000Source | -191,086,000Source | -227,461,000Source | -106,793,000Source | -119,204,000Source |
| Operating ExpensesUSD | — | — | 58,152,000Source | 76,439,000Source | 39,727,000Source | 67,090,000Source | 44,179,000Source | 85,913,000Source | 260,851,000Source | 300,496,000Source | 243,009,000Source | 196,715,000Source |
| Operating Lease, ExpenseUSD | — | — | 2,000,000Source | 2,000,000Source | 1,600,000Source | 2,000,000Source | 1,600,000Source | 2,000,000Source | 7,900,000Source | 7,900,000Source | 7,000,000Source | 6,200,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 25,000,000Source | 11,971,000Source | 56,270,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 28,000Source | 0Source | 4,000Source | 271,000Source | 314,000Source | 268,000Source |
| Restructuring CostsUSD | — | — | 9,558,000Source | 0Source | 201,000Source | 18,422,000Source | 42,000Source | 21,043,000Source | 53,415,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 9,693,000Source | 8,520,000Source | 9,839,000Source | 63,745,000Source | 14,523,000Source | 17,399,000Source | 102,484,000Source | 62,043,000Source | 153,731,000Source | 67,772,000Source |
| Operating Income (Loss)USD | — | — | -48,459,000Source | -67,919,000Source | -29,888,000Source | -3,345,000Source | -29,656,000Source | -68,514,000Source | -158,367,000Source | -238,453,000Source | -89,278,000Source | -128,943,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -56,857,000Source | -48,787,000Source | -38,532,000Source | -11,517,000Source | -38,499,000Source | -75,961,000Source | -191,179,000Source | -225,098,000Source | -88,601,000Source | -116,704,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 1,000Source | -18,000Source | -15,000Source | 7,000Source | -93,000Source | 2,363,000Source | 18,192,000Source | 2,500,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -56,857,000Source | -48,787,000Source | -38,533,000Source | -11,499,000Source | -38,484,000Source | -75,968,000Source | -191,086,000Source | -227,461,000Source | -106,793,000Source | -119,204,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | -2.33Source | -1.35Source | -2.94Source | -9.08Source | -22.49Source | -2.96Source | -1.78Source | -2.35Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | -2.33Source | -1.35Source | -2.94Source | -9.08Source | -22.49Source | -2.96Source | -1.78Source | -2.35Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 16,571,602Source | 8,511,985Source | 13,082,355Source | 8,364,294Source | 8,497,798Source | 76,829,198Source | 60,163,542Source | 50,739,185Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 16,571,602Source | 8,511,985Source | 13,082,355Source | 8,364,294Source | 8,497,798Source | 76,829,198Source | 60,163,542Source | 50,739,185Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -93,000Source | 2,363,000Source | 18,192,000Source | 2,500,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | 0Source | 32,139,000Source | — | 4,074,000Source |
| General and Administrative ExpenseUSD | — | — | 8,741,000Source | 14,331,000Source | 7,831,000Source | 10,343,000Source | 7,584,000Source | 13,273,000Source | 41,019,000Source | 48,453,000Source | 62,584,000Source | 59,544,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -191,179,000Source | — | — | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | 1,300,000Source | 2,400,000Source |
| Operating ExpensesUSD | — | — | 58,152,000Source | 76,439,000Source | 39,727,000Source | 67,090,000Source | 44,179,000Source | 85,913,000Source | 260,851,000Source | 300,496,000Source | 243,009,000Source | 196,715,000Source |
| Operating Lease, ExpenseUSD | — | — | 2,000,000Source | 2,000,000Source | 1,600,000Source | 2,000,000Source | 1,600,000Source | 2,000,000Source | 7,900,000Source | 7,900,000Source | 7,000,000Source | 6,200,000Source |
| Research and Development ExpenseUSD | — | — | 39,853,000Source | 62,108,000Source | 31,695,000Source | 38,325,000Source | 36,553,000Source | 51,597,000Source | 166,417,000Source | 252,043,000Source | 180,425,000Source | 137,171,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | — | — | — | — | 12,300,000Source | — | 12,600,000Source | — | — | — |
| Restructuring CostsUSD | — | — | 9,558,000Source | 0Source | 201,000Source | 18,422,000Source | 42,000Source | 21,043,000Source | 53,415,000Source | — | — | — |
Offerings
Registration 333-294541
Filing attachments
stro-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 stro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study - Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study - - Strong execution of STRO-004 STRIVE-01 Study with rapid enrollment of initial dose escalation cohorts within 7 months; do…
Read attachment ↗stro-ex99_2.htm · 8-K · 2026-08-12
EX-99.2 3 stro-ex99_2.htm EX-99.2 August 2026 NASDAQ: STRO Exhibit 99.2 Sutro Biopharma Logo This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our future financial performance; busin…
Read attachment ↗stro-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 stro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights - On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 - - Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 - - First dual-payload iADC fro…
Read attachment ↗d12152830_ex99-1.htm · SCHEDULE 13G · 2026-05-01
EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗d115714dex45.htm · S-3 · 2026-03-23
Exhibit 4.5 FORM OF DEBT SECURITY [Face of Security] SUTRO BIOPHARMA, INC. [If applicable, insert - FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURITY IS % AND THE ISSUE DATE IS ] [IF THE SECURITY IS A GLOBAL SECURITY, INSERT…
Read attachment ↗d115714dex46.htm · S-3 · 2026-03-23
Exhibit 4.6 SUTRO BIOPHARMA, INC. And , as Trustee INDENTURE Dated as of, TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION …
Read attachment ↗